Road to RAD: Nemolizumab for AD

In a recent interview with Dermatology Times, Jonathan Silverberg, MD, PhD, MPH, professor of dermatology at George Washington University School of Medicine and Health Sciences, discussed the results of the recent ARCADIA studies, which ultimately led to the approval of nemolizumab for atopic dermatitis (AD).

“The ARCADIA studies showed significance on a number of endpoints: rapid onset of efficacy, particularly with respect to itch, treatment success with respect to improvements of IGA scores, EASI75 response rates, quality of life, sleep disturbances, and a variety of other endpoints,” Silverberg stated.

Silverberg, a co-chair of the conference, will be presenting on a number of topics, including new and upcoming therapies, managing itch, and more. He will be joined by co-chair Raj Chovatiya, MD, PhD, MSCI; Dermatology Times Editor in Chief Christopher Bunick, MD, PhD; Mona Shahriari, MD; and even more experts in the field. With presentations on everything from dose flexibility to late breaking research, there is sure to be something for everyone at RAD 2025.

Want to hear more pearls and expert insights on AD? Join us at the annual Revolutionizing Atopic Dermatitis Conference this June in Nashville, TN. Use code DT40 for 40% off your RAD 2025 registration.

For more expert insights on the topic, check out our conference coverage page. To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.